The combination of accelerating YCANTH adoption, international expansion with Torii, reduced burn, and a clear path to EU approval creates multiple near-term value inflection points. The cash runway into 2027 supports advancement of the Phase 3 programs without immediate dilution risk.
Price Chart
Executive Summary
Verrica Pharmaceuticals reported strong 2025 financial results with total revenue surging 370% year-over-year to $35.6 million, driven by a 130% increase in YCANTH net product revenue and $20.3 million in license/collaboration revenue from its Torii partnership. The company significantly improved its financial position by eliminating $35 million in debt, extending cash runway into Q1 2027, and cutting SG&A expenses by over 40%.
Key Financial Metrics
Key Facts
- Total revenue grew 370% YoY to $35.6 million in 2025 ($15.3M product, $20.3M collaboration)
- YCANTH net revenue up 130% to $15.3 million; dispensed units grew 99% to 51,296
- SG&A expenses decreased over 40% to $35.2 million from $58.8 million in 2024
- Company repaid $35 million in debt and extended cash runway into Q1 2027
- First patient dosed in Phase 3 trial for common warts; FDA aligned on Phase 3 path for VP-315 in basal cell carcinoma
- EMA confirmed no additional clinical studies needed for YCANTH EU approval filing
Financial Impact
Revenue increased by $28 million year-over-year, with $18 million from Torii milestones. SG&A reduced by $23.6 million. Net loss narrowed from $76.6M to $17.9M.
Risk Factors
- Continued net losses despite revenue growth
- Dependence on successful execution of Phase 3 trials for common warts and BCC
- Commercial execution risk in scaling YCANTH adoption beyond current trajectory
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253711 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 6w ago | Press Release | $4.95 $4.18 | ▼ −15.56% | ▼ −17.68% | $3.42 (−30.91%) |
Jun 9, 2026 19w ago | 8-K | $5.75 $6.53 | ▲ +13.57% | ▲ +9.94% | $3.42 (−40.52%) |
May 12, 2026 23w ago | 8-K | $7.37 $6.03 | ▼ −18.25% | ▼ −17.64% | $3.42 (−53.60%) |
May 12, 2026 23w ago | Press Release | $7.37 $6.03 | ▼ −18.25% | ▼ −17.64% | $3.42 (−53.60%) |
Apr 20, 2026 27w ago | DEFA14A | $6.32 $5.87 | ▼ −7.12% | ▼ −12.04% | $3.42 (−45.89%) |
Mar 11, 2026 32w ago | Press Release | $6.26 $5.83 | ▼ −6.87% | ▼ −7.39% | $3.42 (−45.37%) |
Mar 4, 2026 33w ago | Court Ruling | $5.20 $5.47 | ▼ −5.19% | ▼ −8.67% | $3.42 (+34.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers